A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

Abstract Background Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined...

Full description

Bibliographic Details
Main Authors: Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert, Nicolai Haertel
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Cancer
Subjects:
Esophageal squamous cell cancer
Elderly
Comprehensive geriatric assessment
Checkpoint inhibitors
Personalized medicine
Geriatric oncology
Online Access:http://link.springer.com/article/10.1186/s12885-019-5446-2

Internet

http://link.springer.com/article/10.1186/s12885-019-5446-2

Similar Items